Entresto 200mg is a prescription cardiovascular medicine from Novartis containing sacubitril and valsartan. Each film-coated tablet provides approximately 97mg sacubitril and 103mg valsartan, corresponding to the combined 200mg strength. The medicine is prescribed for selected patients with heart failure as part of specialist-directed cardiovascular care. This presentation contains 56 tablets.
Entresto 200mg must be taken according to the prescribing physician's instructions. The recommended adult target maintenance dose is commonly one 200mg tablet twice daily, when tolerated. Treatment usually begins at a lower strength, with adjustments based on blood pressure, kidney function and individual circumstances. Tablets may be taken with or without food. They should be swallowed with water without independently changing the prescribed dose. Entresto must not be taken together with an ACE inhibitor; a 36-hour separation is required when switching between these medicines. Blood pressure, kidney function and potassium levels may require monitoring. The medicine must not be used during pregnancy. Seek urgent medical attention if swelling of the face, lips or tongue occurs.
Sacubitril inhibits neprilysin after conversion to its active metabolite, supporting the activity of naturally occurring peptides involved in cardiovascular regulation. Valsartan blocks angiotensin II type 1 receptors, reducing effects associated with blood vessel constriction and fluid retention. These complementary actions help support cardiovascular function in suitable patients with heart failure. The combination is used within a structured medical management plan.
Each tablet contains sacubitril and valsartan in a combined strength of 200mg. Additional ingredients include microcrystalline cellulose, low-substituted hydroxypropylcellulose, crospovidone, magnesium stearate, talc and colloidal anhydrous silica. The film coating contains hypromellose, macrogol 4000, titanium dioxide, and red and black iron oxides. The complete formulation appears in the patient leaflet.
Entresto 200mg provides a combination of two complementary cardiovascular ingredients for medically supervised heart failure care. Its fixed-dose tablet format supports a structured prescription schedule and ongoing clinical monitoring.
Entresto is a Novartis medicine. The 200mg, 56-tablet presentation is registered with manufacturing by Novartis Farma S.p.A. in Italy in one regional market; manufacturing may differ for the Kuwait pack. Store in the original packaging, protected from moisture. It is available at Pharmacy Plus Kuwait.